Mirtazapina Flas Normogen (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes serotonin 5‑HT2 and 5‑HT3 receptors and histamine H1 receptors, resulting in enhanced serotonergic and noradrenergic neurotransmission while providing sedative and appetite‑stimulating effects.

The specific dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to therapeutic goals and any observed side effects, following local prescribing guidelines.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine differs from selective serotonin reuptake inhibitors (SSRIs) by its dual noradrenergic and specific serotonergic activity and strong antihistamine effect, which often leads to sedation and weight gain. It may be preferred when patients need a sedating agent or have poor response to SSRIs, but individual response varies.

Mirtazapina Flas Normogen should be stored at temperatures below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

The product is taken orally, usually once daily in the evening, with or without food. The exact timing and whether it should be taken with meals are determined by the prescribing clinician based on patient tolerance and therapeutic goals.

Serious risks include the potential for suicidal thoughts or behaviors, especially early in treatment, agranulocytosis or severe neutropenia, seizures, significant hypotension, hepatic dysfunction, and serotonin syndrome when combined with other serotonergic drugs.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate mania.